← Back to Clinical Trials
Recruiting NCT06518421

NCT06518421 Emotion and Memory in Chronic Neuropathic Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06518421
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Trigeminal Neuralgia
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2024-02-12
Primary Completion 2027-02-12

Trial Parameters

Condition Trigeminal Neuralgia
Sponsor University Health Network, Toronto
Study Type OBSERVATIONAL
Phase N/A
Enrollment 400
Sex ALL
Min Age 35 Years
Max Age 60 Years
Start Date 2024-02-12
Completion 2027-02-12
Interventions
Neuropsychological assessmentsMR Imaging

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Chronic pain affects one in four Canadians, leading to severe personal and societal costs. Over 70% of chronic pain patients report memory difficulties and fear having unexpected pain. Abnormalities in brain structures associated with emotion and memory, including the hippocampus and amygdala, can be affected by chronic pain. Understanding the relationship between chronic pain, structural brain changes, and cognitive functioning will lead to improved diagnosis, treatment, and outcomes in chronic pain disorders. In this project, the investigators will use advanced brain imaging techniques that assess the structure and function of the brain along with cognitive assessments to examine the overlap between chronic pain and emotion-memory processes. The study team will conduct the study using an excellent model of chronic pain-trigeminal neuralgia, a severe form of facial pain that responds well to surgical treatment. Brain images and cognitive data will be collected from participants before and after surgical treatment for pain. This information will be analyzed and compared with age- and sex-matched healthy individuals. This study will be the first to thoroughly investigate relationships between brain structure and function, cognition (memory, emotion), and promises to impact our understanding of chronic neuropathic pain conditions.

Eligibility Criteria

Inclusion Criteria (for HC and TN): * Age between 35 and 60 years old * Absence of other active major neurological or psychiatric disorders * Absence of MRI contraindications * Able to communicate sufficiently to complete tasks and questionnaires * Montreal Cognitive Assessment (MoCA) score greater than 23/30 (MoCA ≤23/30 could indicate severe cognitive impairment) Inclusion Criteria for TN: * Experiencing TN pain over a period of 6 months * Stable medication use * Meet established diagnostic criteria for TN (ICHD-3) Exclusion Criteria (both HC and TN): * Presence of other chronic pain/headache conditions * Untreated hypertension or diabetes mellitus * History of chronic drug or substance use disorder, chronic use of opioids or steroids, head trauma affecting cognitive performance, * History/presence of active psychiatric illness and/or current use of psychoactive medication * History of multiple sclerosis, skull base injury or tumours

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology